Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepu Madduri

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
PET Clinics|May 16, 2019
PET-Computed Tomography in Myeloma: Current Overview and Future DirectionsDeepu Madduri, Bart Barlogie
Blood Cancer Journal|November 26, 2024
CAR-T cell therapy in Multiple Myeloma: current status and future challengesDawn Swan, Deepu Madduri, Jay Hocking
Cancer Journal (Sudbury, Mass.)|September 22, 2021
Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the SpotlightBo Wang, Sridevi Rajeeve, Deepu Madduri
Therapeutic Advances in Hematology|June 23, 2020
Selinexor in relapsed/refractory multiple myelomaJoshua Richter, Deepu Madduri, Shambavi Richard, et al.
Future Oncology (London, England)|July 27, 2023
Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myelomaThomas G Martin, Deepu Madduri, Lida Pacaud, et al.
Therapeutic Advances in Hematology|April 2, 2021
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapiesLarysa Sanchez, Alexandra Dardac, Deepu Madduri, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 21, 2022
Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple MyelomaThomas Martin, Carolyn C Jackson, Lida Pacaud, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 21, 2019
SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging AgentsDeepu Madduri, Madhav V Dhodapkar, Sagar Lonial, et al.
Future Oncology (London, England)|July 5, 2023
Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myelomaJesus G Berdeja, Adam D Cohen, Thomas Martin, et al.
Future Oncology (London, England)|February 1, 2021
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USADeepu Madduri, May Hagiwara, Kejal Parikh, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
PET Clinics|May 16, 2019
PET-Computed Tomography in Myeloma: Current Overview and Future DirectionsDeepu Madduri, Bart Barlogie
Blood Cancer Journal|November 26, 2024
CAR-T cell therapy in Multiple Myeloma: current status and future challengesDawn Swan, Deepu Madduri, Jay Hocking
Cancer Journal (Sudbury, Mass.)|September 22, 2021
Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the SpotlightBo Wang, Sridevi Rajeeve, Deepu Madduri
Therapeutic Advances in Hematology|June 23, 2020
Selinexor in relapsed/refractory multiple myelomaJoshua Richter, Deepu Madduri, Shambavi Richard, et al.
Future Oncology (London, England)|July 27, 2023
Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myelomaThomas G Martin, Deepu Madduri, Lida Pacaud, et al.
Therapeutic Advances in Hematology|April 2, 2021
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapiesLarysa Sanchez, Alexandra Dardac, Deepu Madduri, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 21, 2022
Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple MyelomaThomas Martin, Carolyn C Jackson, Lida Pacaud, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 21, 2019
SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging AgentsDeepu Madduri, Madhav V Dhodapkar, Sagar Lonial, et al.
Future Oncology (London, England)|July 5, 2023
Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myelomaJesus G Berdeja, Adam D Cohen, Thomas Martin, et al.
Future Oncology (London, England)|February 1, 2021
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USADeepu Madduri, May Hagiwara, Kejal Parikh, et al.
Pageof 5